ArticleNPJ precision oncology2025
A signal-seeking phase 2 study of tremelimumab in advanced cancers with high tumour mutational burden.
Subotheni Thavaneswaran et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it